Dr. Sergey A. Tarasov
My Social Links

Dr. Sergey A. Tarasov

Assistant Professor
Materia Medica Holding Company, Russia

Highest Degree
Ph.D. in Pharmacology from Goldberg Research Institute of Pharmacology, Russia

Share this Profile

Biography

Dr. Sergey A. Tarasov is currently working as Head of Research & Analytical Department of Russian Pharmaceutical Company Materia Medica Holding Russia. He obtained his Ph.D. in Pharmacology from Goldberg Research Institute of Pharmacology, Russia. His field of interest related to Antiviral Drugs Development, Immunology & Immunotherapy, Molecular Medicine, and Biotechnology of Antibodies. He is member of American Society for Microbiology, and Associate Editor of International Journal of Pharmacology. He is author and coauthor of 7 journal papers and 12 presentations in international congress.

Area of Interest:

Pharmacology and Toxicology
100%
Drug Development
62%
Preclinical Study
90%
Molecular Pharamcology
75%
Regulatory Toxicology
55%

Research Publications in Numbers

Books
0
Chapters
0
Articles
0
Abstracts
0

Selected Publications

  1. Gorbunov, E.A., J. Nicoll, E.V. Kachaeva, S.A. Tarasov and O.I. Epstein, 2015. Subetta increases phosphorylation of insulin receptor β-subunit alone and in the presence of insulin. Nutr. Diabetes, Vol. 5. 10.1038/nutd.2015.20.
    CrossRef  |  PubMed  |  Direct Link  |  
  2. Sakat, S.S., K. Mani, Y.O. Demidchenko, E.A. Gorbunov, S.A. Tarasov, A. Mathur and O.I. Epstein, 2014. Release-active dilutions of diclofenac enhance anti-inflammatory effect of diclofenac in carrageenan-induced rat paw edema model. Inflammation, 37: 1-9.
    CrossRef  |  Direct Link  |  
  3. Pschenitza, M., Е.S. Gavrilova, S.А. Tarasov, D. Knopp, R. Niessner and О.I. Epstein, 2014. Application of a heterogeneous immunoassay for the quality control testing of release-active forms of diclofenac. Int. Immunopharmacol., 21: 225-230.
    CrossRef  |  Direct Link  |  
  4. Gavrilova, E.S., S.A. Bobrovnik, G. Sherriff, A.A. Myslivets, S.A. Tarasov and O.I. Epstein, 2014. Novel approach to activity evaluation for release-active forms of anti-interferon-gamma antibodies based on enzyme-linked immunoassay. PLoS ONE, Vol. 9. 10.1371/journal.pone.0097017.
    CrossRef  |  Direct Link  |  
  5. Nicoll, J., E.A. Gorbunov, S.A. Tarasov and O.I. Epstein, 2013. Subetta treatment increases adiponectin secretion by mature human adipocytes in vitro. Int. J. Endocrinol., Vol. 2013. 10.1155/2013/925874.
    CrossRef  |  Direct Link  |  
  6. Bailbe, D., E. Philippe, E. Gorbunov, S. Tarasov, O. Epstein and B. Portha, 2013. The novel oral drug Subetta exerts an antidiabetic effect in the diabetic Goto-Kakizaki rat: Comparison with rosiglitazone. J. Diabetes Res., Vol. 2013. 10.1155/2013/763125.
    CrossRef  |  Direct Link  |  
  7. Tarasov, S.A., V.V. Zarubaev, E.A. Gorbunov, S.A. Sergeeva and O.I. Epstein, 2012. Activity of ultra-low doses of antibodies to gamma-interferon against lethal influenza A(H1N1)2009 virus infection in mice. Antiviral Res., 93: 219-224.
    PubMed  |  Direct Link  |  
  8. Shishkina, L.I., M.O. Skarnovich, A.S. Kabanov, A.A. Sergeev and S.A. Tarasov et al., 2011. [Study of efficacy of anaferon pediatric in mice infected by pandemic influenza virus A(H1N1/09)v]. Zh. Mikrobiol. Epidemiol. Immunobiol., 1: 83-86, (in Rissian).
    PubMed  |  
  9. Shishkina, L.N., M.O. Skarnovich, A.S. Kabanov, A.A. Sergeev and S.E. Olkin, et al., 2010. Antiviral activity of Anaferon (pediatric formulation) in mice infected with pandemic influenza virus A(H1N1/09). Bull. Exp. Biol. Med., 149: 612-614.
    PubMed  |  Direct Link  |  
  10. Zhavbert, E.S., M.V. Kachanova, S.A. Tarasov, Y.L. Dugina and S.A. Sergeeva, et al., 2009. Evaluation of the efficiency and safety of combined treatment with impaza and nitrates in CHD patients with erectile dysfunction. Bull. Exp. Biol. Med., 148: 325-327.
    CrossRef  |  Direct Link  |  
  11. Timchenko, V.N., E.B. Pavlova, T.M. Chernova, S.L. Bannova and T.I. Savel'eva, et al., 2009. Evaluation of the efficiency and safety of anaferon (pediatric formulation) in the treatment of chickenpox in children. Bull. Exp. Biol. Med., 148: 291-294.
    PubMed  |  Direct Link  |  
  12. Tarasov, S.A., M.V. Kachanova, E.S. Zhavbert, Y.L. Dugina and O.I. Epshtein, et al., 2009. Application of ultralow doses of antibodies to interferon-gamma in complex therapy of bacterial infections and prophylaxis of bacterial complications. Bull. Exp. Biol. Med., 148: 295-296.
    PubMed  |  Direct Link  |  
  13. Petrov, V.I., S.V. Nedogoda, O.I. Epshtein, T.A. Chalyabi and U.A. Brel', et al., 2009. The use of ultralow doses of antibodies to C-terminal fragment of angiotensin II AT1 receptor (kardos) in the therapy of arterial hypertension. Bull. Exp. Biol. Med., 148: 332-334.
    PubMed  |  Direct Link  |  
  14. Petrov, V.I., A.R. Babaeva, E.V. Cherevkova, M.V. Kachanova and Y.A. Zabolotneva et al., 2009. Efficiency and safety of long-term artrofoon treatment in rheumatoid arthritis. Bull. Exp. Biol. Med., 148: 486-488.
    CrossRef  |  Direct Link  |  
  15. Markel', A.L., E.S. Zhavbert, S.A. Tarasov, Y.L. Dugina and M.V. Kachanova, et al., 2009. Effect of impaza on cardiovascular system. Bull. Exp. Biol. Med., 148: 518-519.
    CrossRef  |  Direct Link  |  
  16. Kudin, M.V., S.A. Tarasov, M.V. Kachanova, A.V. Skripkin and Y.N. Fedorov, 2009. Anaferon (pediatric formulation) in prophylactics of acute respiratory viral infection in children. Bull. Exp. Biol. Med., 148: 279-282.
    PubMed  |  Direct Link  |  
  17. Zhavbert, E.S., S.A. Tarasov, J.L. Dugina, S.A. Sergeeva and S.I. Gamidov, et al., 2008. Study of the correlation between clinical efficiency of impaza and serum ADMA level. Bull. Exp. Biol. Med., 145: 367-370.
    PubMed  |  Direct Link  |  
  18. Voronina, T.A., G.M. Molodavkin, E.S. Zhavbert, S.A. Tarasov and I.A. Kheyfets, et al., 2008. Anxiolytic and antidepressant characteristics of impaza. Bull. Exp. Biol. Med., 145: 735-737.
    PubMed  |  Direct Link  |  
  19. Vasil'ev, A.N., S.A. Sergeeva, M.V. Kachanova, S.A. Tarasov and Elfimova UV, et al., 2008. Use of ultralow doses of antibodies to gamma-interferon in the treatment and prophylaxis of viral infections. Antibiot. Khimioter., 53: 32-35.
    PubMed  |  Direct Link  |  
  20. Shishkina, L.N., A.N. Sergeev, A.S. Kabanov, M.O. Skarnovich and N.K. Evtin, et al., 2008. Study of efficiency of therapeutic and preventive anaferon (pediatric formulation) in mice with influenza infection. Bull. Exp. Biol. Med., 146: 763-765.
    PubMed  |  Direct Link  |